Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nazartinib vs Investigator's Choice in First-Line EGFR-Mutated NSCLC
NCT03529084Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Jul 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of nazartinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Planned start Jul 2018; status: withdrawn.
02
Drugs
nazartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03529084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529084.